The startup provides molecular diagnostic testing services that utilize sample-to-answer methodologies to deliver actionable clinical reports. This approach enhances the accuracy of healthcare management by enabling timely and effective decision-making for doctors and patients.
Funding
$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Conventional diagnostic methods for infectious diseases, genetic disorders, and cancer often suffer from slow turnaround times and limited sensitivity, delaying appropriate treatment decisions. Traditional methods may also lack the ability to detect multiple pathogens or genetic markers simultaneously, requiring multiple tests and increasing costs.
Solution
Rivaara Labs offers a comprehensive suite of molecular diagnostic testing services utilizing real-time PCR technology to provide rapid, accurate, and actionable clinical reports. Their sample-to-answer solutions cover a wide range of diagnostic domains, including infectious diseases, genetic disorders, and oncology. Rivaara's multiplex panels enable simultaneous detection of multiple pathogens or genetic markers from a single sample, improving diagnostic efficiency and reducing costs. The company's services aim to equip doctors with relevant, rapid, and accurate diagnostics at an affordable cost, ultimately benefiting patients through timely and superior clinical outcomes.
Target Audience
Rivaara Labs primarily serves doctors, hospitals, and diagnostic centers seeking rapid, accurate, and comprehensive molecular diagnostic testing services for infectious diseases, genetic disorders, and oncology.
Features
- Sample-to-answer solutions with clinically actionable reports
- Real-time PCR technology for rapid and accurate results
- Multiplex panels for simultaneous detection of multiple pathogens or genetic markers
- RespiQuik panels for diagnosing respiratory infections, including viral, bacterial, and fungal pathogens, as well as drug resistance genes
- SeptiQuik panels for diagnosing sepsis, including bacterial and fungal pathogens, as well as drug resistance genes
- MeningoQuik panels for diagnosing central nervous system infections, including bacterial, viral, and fungal pathogens
- Comprehensive Gastroenteritis Panel for qualitative detection of multiple gastrointestinal pathogens
- Panels for detecting and quantifying viral loads of Hepatitis B, Hepatitis C, HIV-1, and CMV
- Panels for detecting and genotyping HPV
- Panels for detecting tuberculosis and drug resistance
- Tests for oncology and genetic disorders